ArticleThe Journal of infectious diseases2024

Phase 1 Open-Label Dose Escalation Trial for the Development of a Human Bacillus Calmette-Guérin Challenge Model for Assessment of Tuberculosis Immunity In Vivo.

Azra Blazevic et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.